CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | N205879 | JANSSEN PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
MITSUBISHI TANABE PHARMA CORPORATION et al v. AUROBINDO PHARMA USA, INC. 2 patentsANDA 213900canagliflozin and metformin hydrochloride | D.N.J. | 2020-03-20 | Terminated 2020-07-17 | — |
MITSUBISHI TANABE PHARMA CORPORATION et al v. MSN LABORATORIES PRIVATE LTD. et al 1 patentANDA 210462, 213403canagliflozin | D.N.J. | 2019-10-14 | Terminated 2020-02-26 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$9.69
per ea
Lowest NADAC/Unit
$9.52
per ea
Brand NDCs
4
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 50458094101INVOKAMET XR 50-1,000 MG TAB | $9.69 | EA | Brand | — | 2026-09-23 |
| 50458094001INVOKAMET XR 50-500 MG TABLET | $9.68 | EA | Brand | — | 2025-12-17 |
| 50458094201INVOKAMET XR 150-500 MG TABLET | $9.56 | EA | Brand | — | 2026-10-21 |
| 50458094301INVOKAMET XR 150-1,000 MG TAB | $9.52 | EA | Brand | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7943582 | Feb 26, 2029PED: Aug 26, 2029 | PED | Yes | Yes | — | |
| 7943582 | Feb 26, 2029PED: Aug 26, 2029 | PED | Yes | Yes | — | |
| 7943582 | Feb 26, 2029PED: Aug 26, 2029 | PED | Yes | Yes | — | |
| 7943788 | Jul 14, 2027PED: Jan 14, 2028 | PED | Yes | Yes | — | — |
| 8513202 | Dec 3, 2027PED: Jun 3, 2028 | PED | Yes | Yes | — | |
| 8513202 | Dec 3, 2027PED: Jun 3, 2028 | PED | Yes | Yes | — | |
| 8513202 | Dec 3, 2027PED: Jun 3, 2028 | PED | Yes | Yes | — |
| Code | Date | Status |
|---|---|---|
| NPP | Dec 18, 2027 | Active |
| PED | Jun 18, 2028 | Active |